FDA approves Amgen drug for lung cancer with specific mutation [Reuters]
Mirati Therapeutics, Inc. (MRTX)
Last mirati therapeutics, inc. earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mirati.com/node/5806
Company Research
Source: Reuters
known as KRAS whose disease has worsened after treatment with chemotherapy or other medicines. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The drug, sotorasib, which will be sold under the brand name Lumakras, shrank tumors with the KRAS mutation in around 36% of patients in clinical trials. The medication is designed to target a gene mutation known as KRAS G12C that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer. Amgen estimates that around 25,000 U.S. patients a year will be eligible for the drug. The KRAS mutation is also found in 1% to 3% of colorectal and other cancers. Lumakras is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of which organ the disease originated. “Today's approval represents a significant step towards a future where more pat
Show less
Read more
Impact Snapshot
Event Time:
MRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRTX alerts
High impacting Mirati Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRTX
News
- Spurs Tycoon Lewis Pleads Guilty To Insider Trading: Prosecutor [Barron's]Barrons
- Billionaire Joe Lewis' Habit of Tipping Off Staff and Lover Lands Him in Court [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Billionaire Joe Lewis' Habit of Tipping Off Staff and Lover Lands Him in Court [BNN Bloomberg (Canada)]BNN Bloomberg
- British billionaire Joe Lewis pleads guilty to insider trading, securities fraud [MSNBC.com]MSNBC.com
- Billionaire Joe Lewis Pleads Guilty in Insider Trading Case [Yahoo! Finance]Yahoo! Finance
MRTX
Earnings
- 8/8/23 - Beat
MRTX
Sec Filings
- 1/23/24 - Form 4
- 1/23/24 - Form 4
- 1/23/24 - Form 4
- MRTX's page on the SEC website